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ABSTRACT
Aberrant activation of Rho GTPase Rac1 has been observed in various tumor 
types, including pancreatic cancer. Rac1 activates multiple signaling pathways that 
lead to uncontrolled proliferation, invasion and metastasis. Thus, inhibition of Rac1 
activity is a viable therapeutic strategy for proliferative disorders such as cancer. 
Here we identified small molecule inhibitors that target the nucleotide-binding site 
of Rac1 through in silico screening. Follow up in vitro studies demonstrated that 
two compounds blocked active Rac1 from binding to its effector PAK1. Fluorescence 
polarization studies indicate that these compounds target the nucleotide-binding 
site of Rac1. In cells, both compounds blocked Rac1 binding to its effector PAK1 
following EGF-induced Rac1 activation in a dose-dependent manner, while showing 
no inhibition of the closely related Cdc42 and RhoA activity. Furthermore, functional 
studies indicate that both compounds reduced cell proliferation and migration in a 
dose-dependent manner in multiple pancreatic cancer cell lines. Additionally, the two 
compounds suppressed the clonogenic survival of pancreatic cancer cells, while they 
had no effect on the survival of normal pancreatic ductal cells. These compounds 
do not share the core structure of the known Rac1 inhibitors and could serve as 
additional lead compounds to target pancreatic cancers with high Rac1 activity.
INTRODUCTION
The Rho family of guanosine triphosphatases 
(GTPases) are important regulators of diverse cellular 
functions including cytoskeleton organization, cell 
cycle progression and motility [1, 2]. Rho GTPases 
can exist either in an active GTP-bound state or in an 
inactive GDP-bound state. The transition between these 
two states is regulated by guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs). 
GEFs promote Rho GTPase activation by facilitating the 
exchange of GDP for GTP. Once activated, Rho GTPases 
can interact with their downstream effectors to activate 
various downstream signaling pathways. GAPs terminate 
the activity of Rho GTPases and downstream signaling by 
promoting GTP hydrolysis and returning Rho GTPases 
to an inactive GDP-bound state [3, 4]. Rac1, Cdc42, and 
RhoA are Rho GTPase family members and have many 
overlapping cellular functions including cytoskeleton 
reorganization, cell cycle regulation, motility and 
cell survival. Accumulating evidence has implicated 
these Rho GTPases as regulators of many aspects of 
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tumorigenesis including proliferation, invasion and 
migration of cells [5–7].
Ras-related C3 botulinum toxin substrate 1 (Rac1), 
a member of the Rho family GTPases, plays a critical 
role in cell migration, cell proliferation, cell survival and 
malignant transformation [8–10]. Rac1 is activated by a 
variety of stimuli, including receptor tyrosine kinases, 
G-protein-coupled receptors, and integrins, by conveying 
signals through Rac-GEFs. Deregulation of upstream 
activators due to activating mutations or increases in the 
levels of growth factors (EGF, HGF, PDGF) leads to 
increased Rac1 activity [11]. Consequently, Rac1 activity 
has been implicated in a number of cancers, including 
breast, colon, prostate, and pancreatic cancer [12–15]. In 
more than 70% of pancreatic cancer, overexpression of 
Rac1 has been observed. Additionally, its hyper-activation, 
caused by overexpression of two of its GEFs, Tiam1 
and Vav1, has been previously documented [15–17]. 
Overexpression of Vav1 has also been associated with poor 
prognosis of pancreatic cancer patients [17, 18]. In a mouse 
model of pancreatic cancer, Rac1 knockdown was shown 
to reduce tumor formation and prolong survival [19]. 
Together, these studies suggest that targeting Rac1 is a 
viable therapeutic strategy for a number of cancers.
Rac1 contains a G (guanine nucleotide-binding)-
domain, which consists of a six-strand β-sheet surrounded 
by α-helices and a 13-residue insertion unique to 
the Rho GTPase family. This encompasses its four 
functional regions, Switch I, Switch II, Insert region, 
and Hypervariable region. The Switch regions are 
responsible for many of Rac1’s molecular interactions 
with Switch I primarily interacting with downstream 
effectors while Switch II interacts with GEFs to regulate 
Rac1 activation [20]. Although there is high sequence and 
structural homology between Rac1, Cdc42, and RhoA, 
interactions with effectors and GEFs are selective among 
these GTPases. Several inhibitors have been developed 
to target the GEF-binding site of Rac1 [21–26]. Many 
GEFs such as Vav1 and Tiam1 that are overexpressed in 
pancreatic cancer are known to promote Rac1 activation 
[15–17, 27]. Although different GEFs bind to Rac1 and 
activate different signaling cascades, the majority of 
Rac1-specific GEFs share a common binding site [28–30]. 
The nucleotide-binding site in Rac1 is considered 
undruggable and to date two inhibitors, MLS000532223 
and EHT1864, have been reported to inhibit Rac1 activity 
by altering nucleotide binding to Rac1 [31, 32]. However, 
their exact mechanism of action is yet to be fully defined. 
Nevertheless, these studies indicate that small molecules 
can be used to disrupt nucleotide binding to Rac1. To 
this end, we performed a structure-based in silico high-
throughput screening to identify small molecule inhibitors 
that target the nucleotide-binding site on Rac1. Here we 
report the identification of two potential small molecules 
with core structures that are dissimilar to previously 
reported Rac1 inhibitors that perturb nucleotide-binding 
to Rac1. The two inhibitors, #1 and #6, are selective for 
Rac1 and reduce cell growth and migration in pancreatic 
cancer cell lines.
RESULTS
Identification and validation of Rac1 GTPase 
inhibitors
To identify novel Rac1 inhibitors that target the 
nucleotide-binding site, a virtual high-throughput screen 
was performed using the 100,000-member ChemBridge 
chemical library. Molegro Virtual Docker was used to 
dock compounds from the library against the crystal 
structure of Rac1 (PDB code: 3TH5). A docking sphere, 
radius 9Å, centered over the nucleotide-binding site 
was generated and the screen was executed using GPU 
accelerated algorithm under default settings. Compounds 
were ranked based on their re-ranked score and the top 
1% of hits were selected for post-docking analysis. Post-
docking analysis included the use of ACD Percepta 
software to assess ADMET and physicochemical 
properties of the hits. Following the post-docking analyses 
a set of 10 compounds were identified for experimental 
characterization.
The set of 10 hit compounds were subjected to a 
cell-based assay to examine their ability to inhibit Rac1 
activity in a pull-down assay previously reported by us 
[33, 34]. CD18/HPAF pancreatic cells were treated for 
2 h with vehicle, 10 μM compound, or positive controls 
(100 μM NSC23766 or 1 mM of GDP) which have 
previously been shown to inhibit Rac1 activation by 
preventing GEF binding [21]. Active Rac1 (Rac1-GTP) 
was then pulled down using GST-tagged Rho GTPase 
binding domain (RBD) of PAK1 (p21-activated serine/
threonine kinase) [35], and analyzed by Western blot 
analysis using a Rac1 specific antibody [33, 34]. Levels of 
Rac1-GTP (Rac1 activity) detected were then normalized 
to total Rac1 levels and represented as a bar graph in 
Figure 1A. This study shows that compounds #1, #5 
and #6 inhibited Rac1 activity at levels comparable to 
NSC23766. It is important to note that the hit compounds 
were tested at 10-fold lower concentration as compared to 
the positive control NSC23766. From this, the two most 
potent, compounds #1 and #6, were selected for further 
studies. 
The binding modes of compounds #1 and #6 
were explored by additional docking experiments 
using Autodock Vina wherein the docking sphere was 
expanded to include all of Rac1. We observed that the 
majority of docked conformations for both compounds 
clustered within the nucleotide-binding pocket of Rac1. 
Figure 1B and 1C summarizes the most favorable docking 
conformation with the lowest energy of compound #1 
(−8.0 kcal/mol) and #6 (-7.6 kcal/mol) and their chemical 
structures. Both compounds are positioned within the 
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guanine recognition site of Rac1; however, neither is 
close enough to make significant contacts with the Switch 
II region of Rac1, which is involved with γ-phosphate 
binding [20]. The clustering of docked structures of 
both compounds to the nucleotide-binding site of Rac1 
indicates that these compounds may act by disrupting 
nucleotide binding.
Compounds #1 and #6 inhibit Rac1 complex 
formation with PAK1
To further evaluate these compounds, we examined 
their effects on the in vitro formation of Rac1-PAK1 
complex using purified recombinant proteins. For this 
analysis, we used full-length Rac1 and titrated increasing 
concentrations of GTP-γS (0.01 – 10 µM), a non-
hydrolysable GTP analog. Active Rac1 (Rac1-GTP-γS) 
was then pulled-down using GST-PAK1 (RBD) 
(Figure 2A, upper panel). Active Rac1 was normalized 
to total Rac1 and showed a dose-dependent increase 
in binding to PAK1. The data was curve fitted and the 
apparent binding affinity was calculated to be 243 ± 93 nM 
(Figure 2A, lower panel). This is comparable to the KD 
from a previous report using a similar assay [36], 
indicating that this assay will be suitable for studying 
formation of Rac1-PAK1 complex in vitro. 
We next examined the effects of compound #1 and 
#6 on the formation of Rac1-PAK1 complex. Increasing 
concentrations (0.001 – 100 µM) of either compound #1 
or #6 were incubated with Rac1 for 1 h and followed by 
additional incubation with GTP-γS and PAK1. As shown 
in Figure 2B, 2C, presence of either compound #1 or #6 
resulted in a dose-dependent decrease in Rac1-PAK1 
interaction with nearly a complete loss in interaction at 
10 µM. Additionally, IC50 values, determined through 
curve fitting, were calculated for compound #1 and #6 as 
95 ± 21 nM and 88 ± 48 nM, respectively (Figure 2B, 2C, 
lower panels). This data suggests that both compounds 
disrupt the formation of Rac1-PAK1 complex with low 
nanomolar potency. 
Compound #1 disrupts the interaction of Rac1 
with mant-GDP
Our preliminary cell-based and cell-free studies 
suggested that both compound #1 and #6 could disrupt 
Rac1 binding to PAK1 and computational studies indicate 
this could be by disruption of nucleotide binding. We 
Figure 1: Identification of compounds #1 and #6 as inhibitors of Rac1. (A) The inhibitory effect on Rac1 activity by a panel of 
compounds identified in a virtual screen. CD18/HPAF cells were incubated with 10 μM of indicated compound for 2 h and Rac1 activity 
(Rac1-GTP) was determined using Rac1 GTPase assay. As positive controls, cells incubated with 100 μM NSC23766 in vivo for 2 h and 
lysate of log-phase growing cells incubated with 1 mM GDP for 15 min in vitro were included in the analysis. Upper panel: Rac1 activity 
(Rac1-GTP) in the samples were analyzed by Western blotting. Lower panel: Immunoblot densities of Rac1-GTP and Rac1 were quantified 
using ImageJ software and relative Rac1 activity versus total Rac1 was determined. Predicted binding modes for compounds #1 (B) and #6 
(C) to the GTP-binding site of Rac1.
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used a previously reported fluorescence polarization 
assay to study the effects of compounds #1 and #6 on 
nucleotide-binding. Fluorescently labeled GDP (mant-
GDP) was incubated with increasing concentrations of 
recombinant Rac1 protein and binding of the nucleotide 
to Rac1 was analyzed using a fluorescence polarization 
assay by monitoring fluorescence polarization of mant-
GDP (λex = 360nm, λem = 440 nm). Results in Figure 2D 
(upper graph) showed a dose-dependent increase in 
fluorescence polarization of mant-GDP following 
addition of Rac1, indicating a dose-dependent binding 
of mant-GDP to Rac1. Using a nonlinear least squares 
fit to a single site-binding model (SigmaPlot 11.0) we 
calculated the apparent binding affinity of 40 ± 10 nM, 
which is comparable to previously reported KD values for 
Rac1-nucleotide binding assays [37, 38]. To investigate 
nucleotide binding in the presence of compound #1, 
increasing concentrations (0.1–1000 µM) of compound 
#1 was incubated with Rac1 (250 nM) for 1 h followed 
by the addition of mant-GDP (100 nM), and fluorescence 
polarization was read after a 10-min incubation. With 
compound #1, we observed a dose-dependent decrease 
in fluorescence polarization, indicating loss of mantGDP 
binding to Rac1. These values were normalized as percent 
bound (Figure 2D, lower graph) and data was fitted using 
a nonlinear least squares fit to a single site-binding model, 
which yielded a Ki of 6.8 ± 1.4 µM. The loss of mant-
GDP binding to Rac1 in the presence of compound #1 
indicates that it acts by inhibiting nucleotide binding to 
Rac1. Due to fluorescence interference by compound #6, 
its effect on nucleotide binding could not be studied using 
this assay.
To validate the specific effect of compound #1 on 
the binding of mant-GDP to Rac1, we tested its effect on 
the binding of mant-GDP to Cdc42, the closest family 
member of Rac1. We first determined the affinity of 
Cdc42 with mant-GDP as described above. Results 
in Figure 2E (upper graph) showed a dose-dependent 
increase in binding of mant-GDP to Cdc42 with a binding 
affinity of 26.0 ± 4.8 nM. However, compound #1 was 
unable to inhibit the binding of mant-GDP to Cdc42 in 
a competition FP assay (Figure 2E, lower graph). Our 
attempts to establish a FP binding assay with mant-GDP 
and RhoA was not fruitful.
Compounds #1 and #6 interferes with Rac1 
activation following EGF stimulation
Since EGF (epidermal growth factor) is a well-
known Rac1 activator in multiple cellular systems 
[17, 39, 40], we evaluated the effects of compounds #1 
and #6 on Rac1 activation following EGF stimulation 
using a PAK1 pull-down assay. CD18/HPAF cells were 
treated with increasing concentrations (1–50 µM) of either 
compound #1 or #6 for 2 h followed by EGF stimulation 
and Rac1 activity was measured. Following treatment, 
both compound #1 (Figure 3A) and #6 (Figure 3B) 
diminished the EGF-induced Rac1 activation in a dose-
dependent manner, with a nearly complete inhibition 
observed at 50 µM for both compounds. Additionally, 
EC50 values determined through curve fitting were 8.3 ± 
1.7 µM for compound #1 and 22.4 ± 3.2 µM for compound 
#6 (Figure 3A, 3B, lower panels). In our hands, EHT-
1864, which was previously shown to interfere with Rac1 
nucleotide exchange [32], did not inhibit Rac1 activation 
in CD18/HPAF pancreatic cancer cells following EGF 
stimulation, as shown in Supplementary Figure 1A. 
Specificity for Rac1 by compounds #1 and #6 
was determined in pancreatic cancer cells 
Rac1, RhoA, and Cdc42, are the most extensively 
studied of the Rho GTPase family. They share many 
overlapping functions in cytoskeleton dynamics, motility, 
cell cycle progression, transcriptional regulation and cell 
survival [7]. All three GTPases are structurally similar, 
sharing a common G-domain fold and a 13-residue 
insertion characteristic of Rho GTPase family members. 
Cdc42 and RhoA also share high sequence homology, 70% 
and 57%, respectively, to Rac1 [41]. Since Rac1 is closely 
related to Cdc42 and RhoA GTPases, we compared the 
cellular effect of compounds #1 and #6 on the activities of 
Rac1, Cdc42 and RhoA. 
To choose the best cell line for the study, we first 
assessed the expression of Cdc42, RhoA and Rac1 in a 
panel of pancreatic cancer cell lines [34]. CD18/HPAF 
cells showed high expression of all three GTPases 
(Figure 4A) and hence was selected for selectivity 
studies [34]. To compare the effect of compounds #1 
and #6 on Rac1, Cdc42, and RhoA, CD18/HPAF cells 
were incubated with 50 μM of either compound #1, #6 
or vehicle control (DMSO) for 2 h. GTP-bound Rac1, 
Cdc42, and RhoA were pulled-down using GST-PAK1, 
GST-WASP or GST-Rhotekin, respectively [21]. Results 
in Figure 4B showed that both compound #1 and #6 
significantly inhibited Rac1 activity in CD18/HPAF cells 
compared to control, whereas they had no inhibitory 
effect on either Cdc42 or RhoA in CD18/HPAF cells. 
Additionally, neither compound affected the steady-state 
protein levels of the three Rho GTPases (Figure 4B). 
These results suggest that compounds #1 and #6 are 
selective for Rac1 GTPase in CD18/HPAF cells.
Compounds #1 and #6 impede proliferation of 
pancreatic cancer cells 
Rac1 activity has been shown to be important 
for proliferation and cell cycle regulation of cancer 
cells [42, 43]. Hence we assessed the effect of the 
compounds on growth kinetics of pancreatic cancer cells 
using an AlamarBlue assay [44]. As shown in Figure 5, 
control-treated Capan1 and CD18/HPAF cells displayed a 
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time-dependent increase in fluorescence intensity, detected 
using AlamarBlue Assay, indicative of exponential growth 
of these cells. However, incubation with compound #1 or 
#6 significantly inhibited the proliferation of these cells 
(*p = < 0.001, n = 6; **p = 0.002). In both cell lines, 
compound #1 showed a greater effect on cell growth when 
compared to compound #6. In Capan1 cells (Figure 5), a 
small but significant decrease in amounts of cells at day 
3 was also observed with compound #1 (red triangles) 
compared to control cells (*p = < 0.001, n = 6). However, 
both compounds showed only a marginal decrease in 
CD18/HPAF cell proliferation at day 3 (Figure 5).
We also compared compound #1 with EHT-1864, an 
inhibitor previously shown to disrupt nucleotide binding 
to Rac family GTPases [32], for their effects on the 
proliferation of pancreatic cancer cells. We observed that 
compound #1 had a better cell growth inhibition profile 
when compared to EHT-1864 in pancreatic cancer cell 
lines. Briefly, AsPC-1 and CD18/HPAF cells treated with 
25 µM compound #1 showed a ~50% and ~20% decrease 
in proliferation, respectively (Supplementary Figure 1B). 
However, 25 µM of EHT-1864 treatment failed to inhibit 
growth of CD18/HPAF cells and inhibited growth of 
AsPC-1 cells by ~20%.
Figure 2: Compounds #1 and #6 block Rac1-PAK1 complex formation. (A) Increasing concentrations of GTP-γS (GTP) 
were incubated with full-length Rac1 in vitro followed by pull-down of Rac1-GTP using GST-PAK1. Upper panel: Rac1-GTP and total 
Rac1 were visualized by immunoblotting. Lower panel: Data were fitted using a nonlinear least squares fit to a single site-binding model 
to determine apparent binding affinities. Rac1 (1 µM) was incubated with compound #1 (B) or #6 (C) at increasing concentrations for 
1 h followed by a 10-min incubation with GTP. Rac1-GTP was then pulled-down using GST-PAK1. Active Rac1 levels were normalized 
to total Rac1 levels. Upper panel: Rac1-GTP was visualized by immunoblotting. Lower panel: Data were fitted using a nonlinear least 
squares fit to a single site-binding model to determine IC50 values. Results are shown as mean ± SD of two experiments. (D) Upper graph: 
Mant-GDP (100 nM) was incubated with increasing concentrations of recombinant Rac1 for 10 min. Binding of mant-GDP to Rac1 was 
monitored using fluorescence polarization (λex = 360 nm, λem = 440 nm) assay. Lower graph: Increasing concentrations of compounds #1 
were incubated with 1 µM Rac1 for 1 h for improved signal-to-noise. Mant-GDP was then added and fluorescence polarization was read 
after 10 min incubation. Values were normalized as percent bound. Data were fitted using a nonlinear least squares fit to a single site-
binding model to determine Ki. Results are shown as mean±S.D. of two sets of experiments done in triplicate. (E) Upper graph: Mant-GDP 
(100 nM) was incubated with increasing concentrations of recombinant Cdc42 for 10 min. Binding of mant-GDP to Cdc42 was monitored 
using fluorescence polarization (λex = 360 nm, λem = 440 nm) assay. Lower graph: Increasing concentrations of compound #1 were incubated 
with 1 µM Cdc42 for 1 h for improved signal-to-noise. Mant-GDP was then added and fluorescence polarization was read after 10 min 
incubation. Values were normalized as percent bound. Data were fitted using a nonlinear least squares fit to a single site-binding model to 
determine Ki. Results are shown as mean ± S.D. of two sets of experiments done in triplicate.
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Figure 3: Inhibition of Rac1 activity in cells by compounds #1 and #6. CD18/HPAF cells were serum starved in the medium 
containing 0.3% FBS for 24 h, incubated for 2 h in the presence of compound #1 (A) or #6 (B) at the indicated concentrations and then 
stimulated with EGF (100 ng/ml) for 5 min. Upper panels: level of Rac1-GTP and total Rac1 in the samples were determined by Rac1 
activity assay and immunoblotting, respectively. Lower panels: immunoblot densities of Rac1-GTP and Rac1 were quantified using ImageJ 
software and relative Rac1 activity versus total Rac1 was determined. The obtained data were fitted using a nonlinear least squares fit to a 
single site-binding model to determine the EC50. Results are shown as mean ± S.D. of two sets of experiments.
Figure 4: Effect of compounds #1 and #6 on the activities of Cdc42 and RhoA GTPases. (A) Expression of Rho GTPases Cdc42 
and RhoA in a panel of pancreatic cancer cell lines (B) CD18/HPAF cells were treated with 50 micromolar compound (#1 or #6) or vehicle 
control for 2 h. Cell lysates were then subjected to pull-down assays using agarose-immobilized GST-WASP, GST-Rhotekin, and GST-PAK1, 
to assess changes in GTP-bound levels of Rho GTPases Cdc42, RhoA, and Rac1, respectively. GTP-bound Cdc42, RhoA, and Rac1 were 
analyzed by Western blot analysis using specific antibodies. Total levels of Cdc42, RhoA, and Rac1 were also analyzed by Western blot 
and are included as controls.
Figure 5: Effect of compounds #1 and #6 on growth kinetics of pancreatic cancer cells. Capan1 and CD18/HPAF pancreatic 
cancer cells were used to test the effect of the compounds on growth kinetics. Cells (1.5 × 103) were plated in 96-well plates, incubated with 
compound (25 μM) or vehicle DMSO for 0, 1, 3, and 5 days and then examined for the amounts of cells using AlamarBlue Assay described 
in the Materials and Methods. Results shown as mean ± S.D. of two sets of experiments done in triplicate. *p = < 0.001 (n = 6); **p = 0.002; 
significant difference between cells treated with compound (#1 or #6) and vehicle control.
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Compounds #1 and #6 reduced migration of 
pancreatic cancer cells
Enhanced cell migration in tumor cells is a 
prerequisite for tumor invasion and metastasis [45]. Rac1 
has been shown to regulate multiple downstream pathways 
that are implicated in cell migration and metastasis [46]. 
To examine how these compounds affect migration, we 
performed wound-healing assays with Capan1 and CD18/
HPAF cells. Cells were plated and allowed to grow to 
90% confluence and wounds were introduced with a 
pipette tip. These plates were then treated with either 
vehicle or compound #1 or #6 (50 µM) and wound healing 
was monitored for 48 h. As shown in Figure 6A, both 
compound #1 (middle panel) and #6 (lower panel) reduced 
the migration of Capan1 cells compared to vehicle control. 
Analyses of the wound closure show that the compounds 
reduced wound closure in Capan1 and CD18/HPAF cells 
at 24 h and had ~60% reduction compared to control at 
48 h (Figure 6B). 
We also examined the dose-dependent effects of 
both compounds on cell migration in both Capan1 and 
CD18/HPAF cells. Briefly, the above experiment was 
conducted with either vehicle or increasing concentrations 
of compound #1 or #6 and their effects on wound closure 
was determined at 48 h. Results in Figure 6C showed 
that treatment with compound #1 in a dose-dependent 
manner reduced migration of both Capan1 (left panel) 
and CD18/HPAF (right panel) cells. Furthermore, Capan1 
cells appeared to be more sensitive to compound #1 
than CD18/HPAF cells. More than 80% reduction in 
wound closure was observed when Capan1 cells were 
treated with 75 µM compound #1 compared to vehicle-
treated cells, while ~60% reduction in wound closure was 
detected in the CD18/HPAF cells with the same treatment. 
Although compound #6 was not as potent as compound 
#1, it also showed dose-dependent inhibition of migration 
of both Capan1 and CD18/HPAF cell lines (Figure 6D), 
with maximum inhibition of ~60% and ~40% inhibition 
respectively. These results indicate that compounds #1 and 
#6 both block cell migration in pancreatic cancer cells.
We validated the inhibitory effect of compound #1 
and #6 on cell mobility using transwell assay. Capan1 
and CD18/HPAF cells were pre-treated for 1 h with either 
vehicle control, or compound (#1 or #6 at 50 µM), re-
seeded into transwells and evaluated for the compounds’ 
effects on the migration of cells through a barrier with 8-µM 
pores. As shown Supplementary Figure 2, the migration 
of both Capan1 and CD18/HPAF cells were significantly 
inhibited by the compound #1 and #6 (p < 0.001, n = 4).
Inhibition of cell viability following treatment 
with compounds #1 and #6
Rac1 activity has been shown to be important to 
survival of cancer cells [42, 43]. We assessed the effect 
of the compounds on cell survival using a clonogenic 
assay. As shown in Figure 7A, treatment with compound 
#1 or #6 for 7 days resulted in decreased survival of 
Capan1 cells compared to vehicle control. We next 
examined these compounds for their dose-dependent 
effects on the viability of pancreatic cancer cells. We used 
Capan1, CD18/HPAF, and AsPC-1 cell lines, which were 
previously shown to have elevated Rac1 level/activity 
compared to normal pancreatic cells [34]. Following 
5-day treatment with increasing concentrations of either 
compound #1 or #6 (0–100 μM), the viability of each cell 
line was determined. Figure 7B (upper panel) showed that 
compound #1 reduced cell viability in a dose-dependent 
manner and ~65% inhibition was observed in all cell 
lines with 50 µM of compound #1 treatment. Similarly, 
compound #6 (Figure 7B, lower panel) also showed dose-
dependent effects on cell viability in all cell lines and 
~75% inhibition was observed at 50 µM. The EC50 values 
were determined through curve fitting and are summarized 
in Table 1.
Next, we examined the effect of compounds #1 
and #6 on the survival of normal pancreatic ductal cells 
(HPNE) in a clonogenic assay. HPNE cells were treated 
for 7 days with increasing concentrations of either 
compound #1 or #6 (0 – 100 μM) and cell survival was 
assessed. As shown in Figure 7C, both compounds had 
little to no effect on the survival of HPNE cells even at the 
highest concentrations compared to controls. Collectively, 
these results suggest that compounds #1 and #6 inhibit the 
survival of pancreatic cancer cells with little effects on the 
survival of normal HPNE cells.
DISCUSSION
It is well established that the hyper-activation of 
Rac1 signaling pathways is associated with numerous 
cancer-associated processes, including proliferation, 
motility, and survival, in multiple cancer cell types 
[42, 47–51]. In pancreatic cancers, Rac1 hyper-activation 
has also been implicated in the development and 
maintenance of Ras-mediated tumorigenesis [19, 52]. We 
have previously observed both elevated Rac1 level and 
elevated Rac1 activity in pancreatic cancer cells compared 
to normal pancreatic ductal cells [34], thus making 
hyper-activated Rac1 a promising therapeutic target for 
pancreatic cancers.
Unlike Ras proteins, activating mutations in 
Rac1 rarely drive the activation of the Rac1 pathway 
[12, 13, 16, 17], with a recently characterized activating 
mutation being Rac1 P29S, identified in melanoma 
[53, 54]. Overexpression of Rac1 and/or its GEFs has 
been shown to drive hyper-activation of Rac1 and its 
downstream pathways [21–25]. This has led to the 
development of Rac1 inhibitors that block GEF binding 
to Rac1. However, these have shown varied efficacy 
in different cell lines and types. This may be due to 
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different tumors utilizing multiple GEFs to activate 
Rac1. In pancreatic cancers, more than 70% of tumors 
overexpressed the Rac1 GEFs Tiam1 and Vav1 [16, 17]. 
These GEFs have different binding modes to Rac1 and 
current Rac1-GEF inhibitors have shown limited efficacy 
against both GEFs [30, 55] indicating the need for 
additional chemotypes for targeting Rac1.
Our objective in this study was to identify inhibitors 
of Rac1 with previously unexplored core structures. 
Towards this goal, a virtual high-throughput screening 
campaign was undertaken with the 100,000-member 
ChemBridge chemical library. The docking sphere was 
selected to include the nucleotide-binding site of Rac1. 
Post-docking analyses and follow up studies identified 
two Rac1 inhibitors, compounds #1 and #6, which 
preferentially clustered to the nucleotide-binding site of 
Rac1. Cell-free and cell-based studies showed that both 
compounds reduced PAK1-binding to active Rac1 in a 
dose-dependent manner with nanomolar potency. 
A nucleotide-binding fluorescence polarization 
assays showed compound #1 inhibits binding of 
fluorescently labeled GDP to Rac1 in a dose-dependent 
manner. This suggests that the biochemical mechanism for 
loss of PAK1 binding to Rac1 by compound #1 could be 
through the nucleotide-binding site. However, impaired 
nucleotide binding could also be caused by displacement 
of Mg2+, a key cofactor in Rac1 nucleotide binding or by 
competing for GEF binding or through unknown allosteric 
mechanisms [36, 37]. Additional biochemical assays as 
well as structural determination of Rac1 in complex with 
each compound (#1 and #6) are needed to clarify the exact 
mechanisms of inhibition. 
Figure 6: Effect of compounds #1 and #6 on mobility of pancreatic cancer cells. Wounds were introduced to Capan1 and 
CD18/HPAF cells at 90% confluence using a pipette tip as described in Materials and Methods. The cells were incubated in the presence 
of DMSO control (0.1%), compound #1 (50 μM) or compound #6 (50 μM) and assessed for wound healing. (A) Representative images of 
cell migration of Capan1 following the indicated treatments. The images were taken at 0 h, 24 h, and 48 h post-wound. (B) Quantitation 
of cell migration of Capan1 (left panel) and CD18/HPAF (right panel) over time after compound or control treatment. Wound closure was 
quantified at 0 h, 24 h, and 48 h post-wound by measuring the remaining un-migrated area. Migration was normalized to relative wound 
closure in vehicle control and shown as mean ± S.D. from two sets of experiments in duplicate samples. *p = < 0.001 (n = 4), significant 
difference in cells exposed to compound #1 or #6 compared to vehicle control. (C) and (D) Cell samples with wounds were treated with 
increasing concentrations of compound #1 and #6 for 48 h and examined for their effects on mobility using wound-healing motility 
assay [65]. Quantitation of migration of Capan1 and CD18/HPAF cells following treatment with compound #1 (C). Quantitation of cell 
migration in Capan1 and CD18/HPAF cells following treatment with increasing concentrations of compound #6 (D). Wound closure was 
quantified by measuring the remaining un-migrated area. Migration was normalized to wound closure in the vehicle control and is shown 
as mean ± S.D. from two sets of experiments in duplicate samples.
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We also evaluated the ability of these compounds 
to block the complex formation of PAK1 with 
intracellular Rac1. Our results showed that both 
compounds were able to dose-dependently inhibit the 
endogenous Rac1 activity in EGF-stimulated CD18/
HPAF cells. Both compounds had EC50 in the low 
micromolar range for inhibition of PAK1 binding to 
Rac1 present in the EGF-stimulated CD18/HPAF cells, 
suggesting that compounds #1 and #6 will be effective in 
the inhibition of sustained hyper-activation of Rac1 seen 
in pancreatic cancer cells.
Selectivity studies in Figure 4 show that the 
compounds #1 and #6 inhibit formation of the Rac1-
PAK1 complex but not the formation of the other two 
GTPases complexes, Cdc42-WASP and RhoA-Rhotekin. 
Consistently, while compound #1 dose-dependently 
inhibited the binding of mant-GDP to Rac1, it had little 
effect on the binding of mant-GDP to Cdc42, even though 
Figure 7: Compounds #1 and #6 inhibit clonogenic survival of pancreatic cancer cells. Pancreatic cancer cells (2 × 103) in 
6-well plates were treated with vehicle, 25 µM or 50 µM of either compound #1 or #6 for 7 days and examined for colonies. (A) Representative 
sample dishes from the clonogenic assay are shown. (B) Viability of the indicated pancreatic cancer cells treated with increasing amounts of 
either compound #1 (upper panel) or #6 (lower panel) were quantified using PrestoBlue reagent, as described in Materials and Methods, and 
the obtained results were normalized to vehicle control. Results are shown as mean ± S.D. from two sets of experiments in duplicate samples. 
(C) HPNE cells were treated with increasing concentrations of compound #1 (green bars) and #6 (blue bars) for 7 days and assessed for 
survival as described above. Upper panel: representative images of HPNE cells treated with vehicle control, 50 µM compound #1 or 50 µM 
compound #6 for 7 days. Lower panel: amounts of the HPNE cells treated with compound #1 or #6 were assessed using ImageJ and obtained 
survival data was normalized to vehicle control. The results are shown as mean ± S.D. from two sets of experiments in duplicate samples.
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there is considerable structural and functional similarity 
with Rac1. Additional biochemical and cell-based studies 
are needed to further characterize the source of the 
observed selectivity of these compounds for Rac1.
Rac1 has been implicated as a cell cycle regulator and 
is known to promote cancer cell proliferation and survival 
[42, 43]. Our studies show that both compounds #1 and #6 
were able to inhibit the viability of pancreatic cancer cells 
at micromolar concentrations. Furthermore, compound #1 
showed a better growth inhibition profile when compared 
to EHT1864 (See Supplementary Figure 1B).
Selectively for cancer cells over normal cells is a 
critical issue for anticancer agents. We thus examined 
the effect of these compounds on the survival of both 
pancreatic cancer cells and immortalized cells derived 
from normal pancreas (HPNE). Our studies indicate that 
both compound #1 and #6 had a significant impact on 
the survival of pancreatic cancer cell lines but no such 
effect was observed with HPNE cells (See Figure 7). 
The mechanistic basis for the observed difference could 
be attributed to the addiction of cancer cells to Rac1 
signaling. Inhibition of Rac1 activity therefore has a 
greater negative effect on pancreatic cancer cell survival 
over HPNE normal pancreatic cells. These observations 
indicate that both compounds could be utilized as viable 
non-toxic therapeutic agents for cancer treatment.
Rho GTPases, in particular Rac1, have long been 
recognized as key regulators of the actin cytoskeleton and 
cell migration [47]. Since cell motility plays a significant 
role in invasion and metastasis of cancer cells, we 
investigated the effects of compounds #1 and #6 on cell 
migration. Our results show that both compound #1 and 
#6 markedly inhibit migration of pancreatic cancer cells 
compared to controls, while compound #1 is more potent 
in the effect (See Figure 6). Additional studies examining 
the ability of compounds #1 and #6 to suppress specific 
Rac1-dependent cytoskeleton rearrangements, such as 
lamellipodia formation, are needed to clarify mechanism 
specific inhibition and to further explore these compounds 
as anti-metastatic therapeutics.
In summary, the present study describes the 
discovery of two small molecule Rac1 inhibitors with 
previously unexplored core structures. We provide 
evidence that both compounds block Rac1-PAK1 complex 
formation possibly by blocking nucleotide association 
to Rac1. Additionally, we show that both compounds 
preferentially down-regulate Rac1 activity compared 
to Cdc42 and RhoA in pancreatic cancer cells. The 
compounds also affect Rac1-regulated processes such 
as cell proliferation and cell migration. We also show 
that neither compound significantly impaired survival of 
normal pancreatic cells even at high concentrations. We 
conclude that compounds #1 and #6 are validated Rac1 
inhibitors that are suitable for hit-to-lead optimization.
MATERIALS AND METHODS
Computational screen
A digital copy of a 100,000 member ChemBridge 
chemical library (San Diego, CA) was screened for 
compounds that could fit into the GTP-binding pocket 
of Rac1 (PDB Code: 3TH5). Compounds were docked 
using Molegro Virtual Docker on the Holland Computing 
Center’s Sandhills Cluster using a docking sphere with a 
9Å radius. The cavity representing the nucleotide binding 
site was identified using a ray-tracing algorithm. The 
docking sphere was centered over the nucleotide binding 
site and the screen was executed using GPU accelerated 
algorithm. The docking grid was set to a resolution of 
0.2 Å. Each compound was allowed three socking runs 
with 256 simultaneous evaluations using 2.0 Å Tabu 
clustering to ensure high conformational diversity between 
poses. All poses were constrained to the 3D space of the 
binding cavity. Poses were then re-evaluated using a more 
comprehensive scoring function, the Molegro re-rank 
score. The compounds were then ranked based on their 
re-ranked score. Structures that ranked in the top 1% (1,000 
structures) were considered for post-docking analysis. Poses 
with re-rank scores outside the 99% confidence interval were 
recommended for bench analysis. For post-docking analysis, 
ACD Percepta software was used to assess ADMET and 
physicochemical properties. Identified compounds were 
obtained from ChemBridge for further testing. 
Table 1: EC
50
 values for compounds #1 and #6 for pancreatic cancer cell viability
Cell Line Compound #1 (μM) Compound #6 (μM)
AsPC-1 19.1 ± 2.5 14.7 ± 0.9
Capan1 21.7 ± 2.4 24.2 ± 1.8
CD18/HPAF 22.5 ± 4.7 23.5 ± 2.2
Pancreatic cancer cells were seeded in 96-well plates at 3 × 103 cells/well for AsPC-1 and 2 × 103 cells/well for Capan1 and 
CD18/HPAF in culture medium. Cells were treated with increasing concentrations of compound #1 or #6 (0, 1.6, 3.1, 6.3, 12.5, 
25, 50 and 100 μM) and incubated for 7 days at 37°C. Viabilities of the treated cells were determined using PrestoBlue reagent 
as described in Material and Methods, and the obtained results were normalized to vehicle control. Half-maximal effective 
concentration (EC50) for the inhibition of clonogenic survival of the indicated cells by each compound was determined using 
SigmaPlot 11.0 software. The results were shown as mean ± S.D. from two sets of experiments in duplicate samples (n = 4).
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Fluorescence polarization assay to assess mant-
GDP binding to Rac1 and determination of IC
50
 
and Ki values
All measurements were made on a 384-well, low-
volume, black, round-bottom polystyrene NBS microplate 
(Corning, New York, NY) using a SpectraMax M5 plate 
reader (Molecular Devices, Sunnyvale, CA). Polarization 
values were measured at excitation wavelength 360 nm 
and emission wavelength 440 nm. Polarization was then 
normalized to percent bound fraction. Binding affinities 
were determined using 100 nM N-methylanthraniloyl 
(mant)-GDP (Life Technologies, Carlsbad, CA) and 
increasing concentrations of His-Rac1 (0.015 nM–150 µM) 
in assay buffer [20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 
10 mM EDTA, and 1 mM MgCl2]. Readings were taken 
after a 10-min incubation. 
IC50 values were determined using increasing 
concentrations of 2 µl of each compound and incubating 
with 17 µL His-Rac1 (250 nM) for 1 h. Then 1 µL of mant-
GDP (100 nM) was added to the reaction mixture and 
measurements were taken after a 10-min incubation. The 
data were then fitted using a nonlinear least squares fit to 
a single site-binding model (SigmaPlot 11.0) to determine 
IC50 values. The Ki values were determined using the 
Coleska-Wang equation [56]. Identical techniques were 
used to determine the apparent binding affinities and 
Ki values for Cdc42 and RhoA. Incubation times were 
increased to 30 min. mant-GDP concentration was 50 nM 
and protein concentration was 200 nM for all competition 
assays. 
Cell culture and treatment
Human pancreatic cancer cell lines AsPC-1, CD18/
HPAF and Capan-1 were obtained from the American 
Type Culture Collection (Manassas, VA) and maintained 
in Dulbecco’s Modified Eagle’s medium containing 
10% fetal bovine serum. HPNE cells are primary human 
pancreatic ductal cells immortalized using hTERT, the 
catalytic subunit of human telomerase [57]. HPNE cells 
were maintained in Medium D medium, which contains 
3 parts of high glucose DMEM (Life Technologies, 
Carlsbad, CA), 1 part of M3F (INCELL, San Antonio, 
TX), 5% fetal bovine serum and 100 ng/ml recombinant 
EGF (Life Technologies) [57].
Rac1 specific inhibitor NSC23766 [21] was obtained 
from Tocris Biosciences (Ellisville, MO). Experimental 
compounds were purchased from ChemBridge (San 
Diego, CA). All compounds were dissolved in DMSO.
Antibodies and recombinant proteins
All antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) unless otherwise 
indicated. These included rabbit IgG for GAPDH (FL-335) 
and PAK1 (2602) (Cell Signaling); mouse IgG for Rac1 
(23A8) (EMD Millipore), Cdc42 (B-8) and RhoA (26C4).
Recombinant PAK1-PBD (70-117aa), WASP-GBD 
(228-298aa), and Rhotekin-RBD (7-89aa) proteins for 
Rac1, Cdc42 and RhoA activity assays, respectively, were 
obtained from Addgene (Cambridge, NH) as glutathione 
S-transferase (GST) fusion proteins. All GST fusion 
proteins were purified as described previously [58]. 
Briefly, each protein was expressed in DH5α E. coli using 
0.1 mM IPTG at 30°C overnight in a shaker incubator. 
Cell pellets were suspended in 10 mM Tris, pH 7.4, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 1 mM DTT. 
Lysis was achieved by adding lysozyme (2 mg/mL), 
13 mM NaCl, and 1% Triton-X 100 and incubated 50 
min at 4°C followed by sonication. Samples were then 
clarified by centrifugation at 25,000 × g for 30 min. The 
supernatant was then incubated with glutathione resin 
(GE Healthcare) for 2 h at 4°C. The resin was washed and 
re-suspended in 20 mM HEPES, pH 7.6, 100 mM KCL, 
1 mM EDTA, 1 mM DTT, and 10% glycerol.
Recombinant Rac1 (1-192aa) was obtained from 
DNASU (Tempe, AZ) as a His-tagged fusion protein. The 
protein was expressed in BL21 (Invitrogen) E. coli using 
1 mM IPTG at 25°C overnight in a shaker incubator. The 
cell pellet was suspended in 50 mM sodium phosphate, 
pH 8.0, 300 mM NaCl, 10 mM MgCl2, 1 mM GDP 
(Chem Impex Intl.), 1 mM PMSF, and 1 mM DTT. Lysis 
was achieved by adding lysozyme (2 mg/mL) and 1% 
Triton-X 100 and incubated 40 min at 4°C followed by 
sonication. Samples were then clarified by centrifugation 
at 25,000 × g for 30 min. The supernatant was then 
incubated with nickel agarose resin (Sigma) for 2 h at 
4°C. The resin was washed in buffer containing 10 mM 
imidazole and transferred to a gravity-flow poly-prep 
chromatography column (Bio-Rad). Rac1 was then eluted 
using 200 mM imidazole followed by dialysis in 20 mM 
Tris, pH 8.0, 50 mM NaCl, 1 mM MgCl2, 1 mM DTT, and 
10% glycerol. Protein concentration was determined using 
a Bradford protein assay (Thermo Scientific) and purity 
was confirmed by SDS-PAGE.
Recombinant GST-Cdc42 (#12969) and 
recombinant 6XHis-RhoA (#73231) were received from 
Addgene. Proteins were expressed in DH5-Alpha cells 
using 1 mM IPTG at 18°C overnight in a shaker incubator 
in LB broth. Cell pellet was suspended in 30 mM Tris-
HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 2 mM 
2-mercaptoethanol. GST-Cdc42 protein was lysed using 
emulsiflex, run over GSTrap 1 mL column (HiTrap) 
using AKTA Pure HPLC system, and eluted using 
buffer containing 20 mM reduced GSH. Fractions were 
then purified using anion exchange chromatography 
(30 mM Tris-HCl pH 7.5, 10 mM NaCl, 5 mM MgCl2, 
2 mM 2-mercaptoethanol, eluted with buffer containing 
1 M NaCl) followed by size exclusion chromatography 
(30 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 
2 mM 2-mercaptoethanol). His-RhoA was lysed using 
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above lysis buffer and run over HisTrap column (HiTrap) 
on AKTA Pure HPLC and eluted using buffer containing 
1 M imidazole. Fractions were then purified using anion 
exchange and size exclusion as described above. Protein 
purity was confirmed by SDS-PAGE.
Immunoblotting, immunoprecipitation and GST 
pull-down assays
Immunoblotting, immunoprecipitation and GST 
pull-down assays were performed as described previously 
[58–60]. Specific protein signals on Western blots were 
visualized by chemiluminescence exposed to x-ray film, 
scanned using EPSON Perfection 4490 PHOTO scanner 
and analyzed using the ImageJ analytical program (NIH, 
Bethesda, MD). 
Rac1, Cdc42 and RhoA activity assays
Rac1, Cdc42 and RhoA activity was assessed using a 
Rac1/Cdc42 assay kit (Upstate Biotechnology, Lake Placid, 
NY), as described previously [61, 62]. Briefly, CD18/
HPAF cells were lysed at 4°C in 50 mM Tris-HCl (pH 7.5) 
containing 10 mM MgCl2, 1% TritonX-100, 1 mM EDTA, 
1 mM EGTA, 2 mM DTT, 5 mM sodium pyrophosphate, 
10 mM sodium 2-glycerolphosphate, 1 μg/ml 
aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mM 
phenylmethylsulfonyl fluoride, 50 mM sodium fluoride, 
and 1 mM sodium vanadate. Cell lysates were incubated 
with agarose beads coated with GST-PAK1, GST-WASP, 
or GST-Rhotekin fusion protein for 1 h to capture GTP-
bound Rac1, Cdc42, or RhoA, respectively. The obtained 
GTP-bound Rac1 (Rac1-GTP), Cdc42 (Cdc42-GTP), or 
RhoA (RhoA-GTP) was resolved on a 15% gel using SDS-
PAGE and assessed by immunoblotting using an anti-
Rac1, anti-Cdc42, or anti-RhoA antibody, as described 
by the manufacturer’s instruction. As a negative control, 
CD18/HPAF cell lysates were incubated with 1 mM GDP 
at 30°C for 15 min and analyzed for Rac1 activity as 
instructed by the manufacturer.
Cell-free Rac1 activity assays were performed using 
5 µg of purified His-Rac1 in 20 µl GTP binding buffer 
[20 mM Tris-HCl (pH 7.6), 100 mM NaCl, 2 mM MgCl2 
and 1 mM DTT) with 1% BSA. For GTP-γS linearity 
tests, increasing concentrations of GTP-γS were added 
to GTP binding buffer containing His-Rac1, incubated 
for 10 minutes at room temperature and followed by 1 h 
incubation with GST-PAK1. GTP-bound Rac1 in the test 
tubes was assessed as described above. To examine the 
compounds’ effects on Rac1 activity in vitro, increasing 
concentrations of each compound was incubated with 
His-Rac1 for 1 h followed by the addition of GTP-γS 
(200 nM) for 10 min. GTP-bound Rac1 was then pulled-
down using agarose beads coated with GST-PAK1, 
separated on a 15% gel using SDS-PAGE and assessed 
by immunoblotting. Apparent binding affinities, EC50, and 
IC50 values were determined by curve fitting the data as 
previously described.
Growth kinetics
Growth kinetics was determined using AlamarBlue 
assay (Life Technologies, Carlsbad, CA) as described 
previously [44]. Cells (1.5 × 103) in 96-well plates were 
incubated with 25 μM compound (#1 or #6) or vehicle 
control for 24, 72, or 120 h and determined for amount 
of cells using PrestoBlue reagent (Life Technologies, 
Carlsbad, CA). Fluorescent measurements were taken 
using a Spectramax M5 plate reader (MDS). Each 
experiment was repeated twice in triplicate.
Cell viability assay
Cells were seeded in 96-well plates at 2 × 103 cells/
well for Capan1 and CD18/HPAF and at 3 × 103 cells/
well for AsPC-1 and HPNE in culture medium. Cells were 
treated with an increasing concentration of compound 
(1.6–100 μM) and incubated at 37°C for up to 7 days. 
Cell viability was determined using PrestoBlue reagent 
(Life Technologies, Carlsbad, CA) according to the 
manufacturer’s protocol. Fluorescent measurements were 
taken using a Spectramax M5 plate reader (MDS). Each 
experiment was repeated twice in triplicate.
Cell mobility examination
Wound healing migration assay: Capan1 and CD18/
HPAF pancreatic cancer cells were seeded in a 6-well 
plate at 90% confluence and wounds were made down the 
central axis of each well using a pipette tip. Cells were 
treated with either compound or vehicle control (DMSO) 
in a dose-dependent manner. Cell migration was visualized 
at magnification 5× using an Axiovert40C scope (Zeiss) 
and photographed with a CoolPIX4300 camera (Nikon). 
Images were taken at 0, 24, and 48 h. Migration was 
analyzed using ImageJ analytical program (NIH, 
Bethesda, MD). Average wound closure was determined 
by averaging the measurements of 15 separate wound 
widths for each data set.
Transwell migration assay: The potential of cells 
to migrate was also assessed in transwell insert with 8.0 
μm pore polycarbonate membrane (BD Biosciences, 
Franklin Lakes). Briefly, cells were pre-treated with either 
compound (50 µM) or vehicle control (DMSO) for 1 h, 
trypsinized and seeded onto the upper chambers of the 
trans-well (0.5 × 105 cells/well) in serum-free DMEM 
medium with/without compound. The lower chambers 
of the transwell were filled with medium containing 10% 
FBS with/without compound. After incubation at 37°C 
and 5% CO2 for 24 h, cells on the upper surface of the 
filter were removed using a cotton swab, whereas cells 
invasive through the filter to the lower surface were fixed 
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with 4% paraformaldehyde for 10 min and stained with 
0.1% crystal violet for 30 min. After staining, the cells 
on the membrane were scanned using EPSON Perfection 
4490 PHOTO scanner and analyzed using the ImageJ 
analytical program (NIH, Bethesda, MD).
Clonogenic survival assays
Clonogenic survival assays were performed as 
described previously [63]. Briefly, pancreatic cancer cells 
were seeded at 2000 cells per well in 6-well plates in 
duplicate. Log-phase growing cells were incubated with 
DMSO as a vehicle control or compound #1 or #6 for 7–14 
days until colonies formed. For HPNE normal pancreatic 
epithelial cells, cells were seeded in a 6-well plate at 30% 
confluence per well in duplicate. Log-phase growing HPNE 
cells were then incubated with DMSO as vehicle control or 
increasing concentrations of compound #1 or #6 for 7 days. 
The colonies were visualized by crystal violet staining and 
analyzed using ImageJ as described previously [64].
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